The stock price of Karyopharm Therapeutics Inc (NASDAQ: KPTI) has dropped by -1.81 compared to previous close of 0.66. Despite this, the company has seen a fall of -6.83% in its stock price over the last five trading days. prnewswire.com reported 2025-01-13 that – Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company On Track to Complete Enrollment in 1H 2025 – – Recently Announced Key Leadership Changes, including the Appointment of Lori Macomber as Chief Financial Officer and Brendan Strong as SVP of Investor Relations and Corporate Communications – – Preliminary Unaudited Full Year 2024 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $145 Million and $113 Million, Respectively – NEWTON, Mass., Jan. 13, 2025 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2024 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2024 achievements and 2025 objectives.
Is It Worth Investing in Karyopharm Therapeutics Inc (NASDAQ: KPTI) Right Now?
Additionally, the 36-month beta value for KPTI is 0.06. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for KPTI is 116.62M and currently, short sellers hold a 16.98% ratio of that float. The average trading volume of KPTI on January 31, 2025 was 1.03M shares.
KPTI’s Market Performance
KPTI’s stock has seen a -6.83% decrease for the week, with a -6.86% drop in the past month and a -23.06% fall in the past quarter. The volatility ratio for the week is 7.30%, and the volatility levels for the past 30 days are at 9.71% for Karyopharm Therapeutics Inc. The simple moving average for the past 20 days is -6.91% for KPTI’s stock, with a -24.84% simple moving average for the past 200 days.
Analysts’ Opinion of KPTI
Many brokerage firms have already submitted their reports for KPTI stocks, with Piper Sandler repeating the rating for KPTI by listing it as a “Overweight.” The predicted price for KPTI in the upcoming period, according to Piper Sandler is $8 based on the research report published on January 19, 2023 of the previous year 2023.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see KPTI reach a price target of $10, previously predicting the price at $7. The rating they have provided for KPTI stocks is “Outperform” according to the report published on November 04th, 2022.
JP Morgan gave a rating of “Neutral” to KPTI, setting the target price at $8 in the report published on February 09th of the previous year.
KPTI Trading at -9.96% from the 50-Day Moving Average
After a stumble in the market that brought KPTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.56% of loss for the given period.
Volatility was left at 9.71%, however, over the last 30 days, the volatility rate increased by 7.30%, as shares sank -4.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.49% lower at present.
During the last 5 trading sessions, KPTI fell by -7.53%, which changed the moving average for the period of 200-days by -43.97% in comparison to the 20-day moving average, which settled at $0.7003. In addition, Karyopharm Therapeutics Inc saw -3.58% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KPTI starting from Paulson Richard A., who sale 4,055 shares at the price of $0.78 back on Jan 06 ’25. After this action, Paulson Richard A. now owns 1,124,257 shares of Karyopharm Therapeutics Inc, valued at $3,175 using the latest closing price.
Paulson Richard A., the President and CEO of Karyopharm Therapeutics Inc, sale 3,620 shares at $0.81 during a trade that took place back on Dec 04 ’24, which means that Paulson Richard A. is holding 1,128,312 shares at $2,932 based on the most recent closing price.
Stock Fundamentals for KPTI
Current profitability levels for the company are sitting at:
- -0.85 for the present operating margin
- 0.96 for the gross margin
The net margin for Karyopharm Therapeutics Inc stands at -0.59. The total capital return value is set at -0.98.
Based on Karyopharm Therapeutics Inc (KPTI), the company’s capital structure generated 5.61 points at debt to capital in total, while cash flow to debt ratio is standing at -0.62. The debt to equity ratio resting at -1.22. The interest coverage ratio of the stock is -3.88.
Currently, EBITDA for the company is -118.42 million with net debt to EBITDA at -2.23. When we switch over and look at the enterprise to sales, we see a ratio of 1.37. The receivables turnover for the company is 4.67for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.00.
Conclusion
In conclusion, Karyopharm Therapeutics Inc (KPTI) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
